Om

Novacyt S.A. is an international molecular diagnostics company that develops, manufactures, and commercializes a broad portfolio of integrated technologies and services, primarily focused on the delivery of genomic medicine. The company offers molecular assays, workflows, and instrumentation for research and clinical applications, enabling seamless end-to-end solutions from sample to result. Its products support sectors including human health, animal health, and environmental testing, with recognition as a leader in reproductive health, precision medicine, and infectious disease. Business units such as Primerdesign, Microgen Bioproducts, and Lab21 Healthcare provide in vitro and molecular diagnostic tests, assays, and reagents supplied worldwide. Novacyt S.A. maintains offices in France, the United Kingdom, Singapore, the United States, and Canada, serving a commercial presence in over 65 countries. Founded in 2006 and headquartered in Le Vésinet, France, the company plays a key role in advancing clinical diagnostics through innovative genomic solutions.

Markedsdata leveret af TwelveData og Morningstar

Aktiemarkedet kan gå både op og ned. Selvom investeringer i aktier historisk set har givet investorer et positivt afkast på langt sigt, er der ingen garanti for fremtidige afkast. Der er derfor en risiko for, at du ikke får de investerede penge tilbage.

INVESTER I NOVACYT MED ENDAVU: Køb Novacyt ($ALNOV) aktier gennem Endavu’s investeringsplatform. Hos Endavu kan du købe og sælge aktier i Novacyt, og handle med aktier, fraktionaler, ETF'er og andre finansielle instrumenter. Endavu tilbyder handel uden kurtage på amerikanske aktier. Endavu tilbyder lav kurtage på tværs af aktier. Handl med over 30.000 forskellige aktier og udenfor markedsåbningstider.